AVITA Medical, Inc. (RCEL) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 21.37
30Y Low1.9·High73.6
ROE
↓
N/A
—
5yr avg: -83.7%
30Y Low-231%·High4%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RCEL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AVITA Medical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $100M | $96M | $331M | $348M | $165M | $292M | $416M | $620M | $691M | $50M | $41M |
| Enterprise Value | $136M | $132M | $363M | $368M | $148M | $238M | $307M | $548M | $671M | $35M | $37M |
| P/E Ratio → | -2.32 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.40 | 1.34 | 5.16 | 6.93 | 4.79 | 8.84 | 14.24 | 43.45 | 126.26 | 39.75 | 34.90 |
| P/B Ratio | — | — | 73.64 | 7.08 | 1.95 | 2.79 | 3.60 | 8.56 | 33.18 | 2.63 | 8.04 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RCEL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.84 | 5.65 | 7.34 | 4.29 | 7.20 | 10.49 | 38.42 | 122.57 | 28.06 | 31.69 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RCEL Profitability
Margins and return-on-capital ratios measuring operating efficiency
AVITA Medical, Inc. earns an operating margin of -58.6%. Operating margins have expanded from -85.1% to -58.6% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 82.1% | 85.8% | 84.5% | 82.4% | 81.5% | 79.6% | 79.2% | 76.8% | 41.2% | 57.2% |
| Operating Margin | -58.6% | -58.6% | -88.1% | -85.1% | -79.9% | -76.1% | -90.8% | -299.2% | -466.4% | -1489.9% | -1073.2% |
| Net Profit Margin | -67.8% | -67.8% | -96.3% | -70.6% | -77.5% | -76.1% | -90.9% | -294.7% | -458.6% | -1370.8% | -975.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -231.0% | -52.9% | -28.2% | -22.8% | -28.3% | -90.2% | -126.1% | -142.7% | -192.3% |
| ROA | -71.4% | -71.4% | -64.6% | -33.7% | -24.9% | -20.8% | -25.6% | -77.7% | -102.9% | -112.2% | -141.5% |
| ROIC | -113.2% | -113.2% | -80.3% | -46.8% | -34.9% | -66.6% | -615.7% | -4788.2% | -771.5% | -497.6% | -473.7% |
| ROCE | -157.4% | -157.4% | -71.6% | -45.9% | -28.3% | -22.3% | -27.5% | -88.9% | -126.3% | -154.3% | -211.6% |
RCEL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $36M ($46M total debt minus $10M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 10.22 | 0.86 | 0.01 | 0.02 | 0.01 | 0.03 | — | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 7.10 | 0.41 | -0.20 | -0.51 | -0.95 | -0.99 | -0.97 | -0.77 | -0.74 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.38 | -8.38 | -10.53 | -29.90 | -1663.31 | -864.69 | -803.73 | — | -933.19 | — | — |
RCEL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.57x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 7.88x to 0.57x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.57 | 0.57 | 2.83 | 7.88 | 8.18 | 10.07 | 16.42 | 10.17 | 5.38 | 5.74 | 2.86 |
| Quick Ratio | 0.46 | 0.46 | 2.47 | 7.46 | 7.98 | 9.84 | 16.20 | 10.02 | 5.22 | 5.44 | 2.45 |
| Cash Ratio | 0.29 | 0.29 | 1.78 | 6.75 | 7.42 | 9.31 | 14.99 | 9.55 | 4.50 | 3.82 | 1.49 |
| Asset Turnover | — | 1.27 | 0.81 | 0.45 | 0.35 | 0.28 | 0.23 | 0.17 | 0.21 | 0.05 | 0.15 |
| Inventory Turnover | 1.85 | 1.85 | 1.25 | 1.39 | 2.84 | 2.86 | 3.61 | 2.64 | 1.71 | 0.64 | 0.49 |
| Days Sales Outstanding | — | 46.31 | 67.96 | 57.66 | 52.60 | 37.87 | 98.43 | 64.16 | 127.42 | 69.74 | 52.60 |
RCEL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AVITA Medical, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $28M | $26M | $25M | $25M | $24M | $20M | $20M | $22M | $9M | $7M |
Peer Comparison
Compare RCEL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RCELYou | $100M | -2.3 | — | — | 82.1% | -58.6% | — | -113.2% | — |
 XTNT | $61M | 14.5 | 5.8 | 6.0 | 62.9% | 5.4% | 10.6% | 8.1% | 2.3 |
 TELA | $36M | -1.0 | — | — | 67.7% | -42.0% | -223.4% | -169.0% | — |
 MDXG | $545M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 APYX | $168M | -14.9 | — | — | 36.0% | -12.2% | -76.9% | -22.1% | — |
 ANGO | $515M | -14.9 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 SYK | $117B | 36.3 | 21.0 | 27.2 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 BSX | $66B | 22.9 | 20.4 | 18.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 ZBH | $17B | 24.5 | 9.8 | 11.6 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
RCEL — Frequently Asked Questions
Quick answers to the most common questions about buying RCEL stock.
What is AVITA Medical, Inc.'s P/E ratio?
AVITA Medical, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
Is RCEL stock overvalued?
Based on historical data, AVITA Medical, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are AVITA Medical, Inc.'s profit margins?
AVITA Medical, Inc. has 82.1% gross margin and -58.6% operating margin.